| Ytd | 16.82% | |
| 1y | 52.25% |
| Open | 4.91 | Prev Close | 4.90 | Low | 4.90 | High | 5.16 | Mkt Cap | 102.98M |
| Vol | 60.18K | Avg Vol | 176.73K | EPS | -1.44 | P/E | N/A | Forward P/E | -1.36 |
| Beta | 1.32 | Short Ratio | 2.29 | Inst. Own | 36.75% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-11 | 50-d Avg | 5.04 | 200-d Avg | 4.66 | 1yr Est | 11.75 |
PYPD News
PolyPid (NASDAQ: PYPD) is approaching a November 28 PDUFA date for D-PLEX100, its lead product candi
PolyPid NASDAQ: PYPD is approaching a November 28 PDUFA date for D-PLEX100, its lead product candida
PolyPid Submitted Marketing Authorization Application to European Medicines Agency for D-PLEX₁₀₀ Las
PETACH TIKVA, Israel, Oct. 01, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or th
PETACH TIKVA, Israel, Sept. 15, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or t
PolyPid Ltd. (PYPD) Q2 2026 Earnings Call Transcript
PolyPid NASDAQ: PYPD said its second-quarter 2026 was marked by the FDA's acceptance of its new drug
PolyPid (NASDAQ:PYPD) reported quarterly losses of $(0.35) per share which beat the analyst consensu
FDA Accepted D-PLEX₁₀₀ NDA with Priority Review; PDUFA Goal Date of November 28, 2026, Approximately
PETACH TIKVA, Israel, July 30, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or th
The FDA did not identify any filing review issues and set a Prescription Drug User Fee Act ("PDU
PDUFA target action date of November 28, 2026, approximately one quarter ahead of Company's previous
Gainers China Pharma Holding (AMEX:CPHI) shares increased by 713.2% to $7.4 during Tuesday's re
HC Wainwright & Co. analyst Brandon Folkes reiterates PolyPid (NASDAQ:PYPD) with a Buy and ma
PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceut
Israeli biotech PolyPid said on Tuesday it had agreed a deal with Azurity Pharmaceuticals to commer
PolyPid to potentially receive over $320 million in upfront and milestone payments, including $30 mi
If approved, D-PLEX100 would address a critical unmet medical need in the prevention of surgical sit
PETACH TIKVA, Israel, May 20, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the
PolyPid NASDAQ: PYPD said its first quarter marked a transition from late-stage clinical development
PolyPid Ltd. (PYPD) Q1 2026 Earnings Call Transcript
Initiated NDA Submission to the FDA for D-PLEX₁₀₀ ; Completion Expected Imminently U.S. Commercial
PETACH TIKVA, Israel, May 06, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the
Analysis demonstrates statistically significant reduction in the severity of surgical wound infectio
Companies Reporting Before The Bell • Sony Group (NYSE:SONY) is projected to report quarterly earni
Companies Reporting Before The Bell • Flex LNG (NYSE:FLNG) is estimated to report earnings for its
On Thursday, 369 companies hit new 52-week lows.
On Tuesday, 647 companies set new 52-week lows.
During Thursday's session, 406 companies made new 52-week lows.
During the session on Thursday, 461 stocks hit new 52-week lows.
Friday's session saw 169 companies set new 52-week lows.
Companies Reporting Before The Bell • Sony Group (NYSE:SONY) is estimated to report quarterly earni
Companies Reporting Before The Bell • Nomad Foods (NYSE:NOMD) is projected to report quarterly earn
On Wednesday, 81 companies hit new 52-week lows.
On Thursday, 175 stocks hit new 52-week lows.
During Wednesday's session, 104 stocks hit new 52-week lows.
On Tuesday, 74 companies achieved new lows for the year.